FORMULATION AND EVALUATION OF IMMEDIATE RELEASE TABLETS CONTAINING ANTIPLATELET DRUGS

Abstract

Various types of therapeutic intervention should be considered for prevention of ACS (Acute coronary syndrome), a clinical syndrome of acute cardiac ischaemia related to coronary artery disease (CAD). These include therapeutic interventions aimed at preventing coronary plaque formation (mainly primary prevention and treatment of risk factors), interventions aimed at preventing plaque rupture (with potential for an anti-inflammatory approach), and interventions aimed at interfering with the final step of thrombosis, i.e., formation of the clot. ASA has for a long time been recommended as a first approach to treating all types of ACS indications, the use of clopidogrel in combination with ASA was approved in Europe, US, and 89 countries worldwide. Clopidogrel in combination with ASA has been more recently approved in Europe, in the US and several other countries for the prevention of atherothrombotic events. This present work, which contains a fixed-dose combination of clopidogrel (75 mg) and acetylsalicylic acid (ASA) (100 mg) as film-coated immediate-release tablet formulations. The use of a fixed-dose combination tablet instead of the individual administration of the two compounds is expected to be more convenient to patients by limiting the number of tablets they need to take.